Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia
Information source: Johns Hopkins University
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Trichiasis
Intervention: azithromycin (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Johns Hopkins University Official(s) and/or principal investigator(s): Sheila K West, Principal Investigator, Affiliation: Johns Hopkins University
Summary
Trachoma, an ocular infection caused by C. trachomatis, is the second leading cause of
blindness worldwide. Years of repeated infection with C. trachomatis cause the eyelid to scar
and contract and ultimately to rotate inward such that eyelashes rub against the eyeball and
abrade the cornea (trichiasis). The World Health Organization (WHO) has endorsed a
multi-faceted strategy to combat trachoma, which includes surgery to correct trichiasis.
Despite this encouraging news, under the best of circumstances the recurrence rate of
trichiasis following surgery is disappointingly high. The objective of our project is to
conduct a randomized, controlled clinical trial of post-surgical antibiotic treatment,
comparing oral azithromycin to topical tetracycline, for trichiasis surgical patients in
Ethiopia with the goal of determining the impact of treatment on rates of trichiasis
recurrence at one and two years.
Clinical Details
Official title: Trial of Antibiotics to Reduce Recurrent Trichiasis (STAR Trial)
Study design: Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: recurrent trichiasis
Secondary outcome: surgical failureadverse events
Detailed description:
A randomized clinical trial of the effectiveness of a single dose of azithromycin compared to
6 weeks of topical tetracycline, and the added benefit of family-based azithromycin
treatment, in preventing recurrence of trichiasis following surgery is proposed. This will
provide the evidence base to inform and change the global public health policy and the
donation program policy, regarding post-surgical treatment for trichiasis patients and
possibly their families.
We will determine the impact of three treatment strategies following trichiasis surgery on
the rate of trichiasis recurrence in the operated eye at six months and one year. To achieve
our objectives, a randomized clinical trial of 1425 trichiasis surgical patients will be
conducted in Sodo,Ethiopia. The first group (Control Group) will receive topical tetracycline
following surgery; the second group (Intervention Patient Group) will receive oral
azithromycin; the third group (Intervention Family Group) will receive oral azithromycin, and
all family members resident in the patient’s household will also receive oral azithromycin.
Data will be collected at baseline (pre-surgery) on ocular status and infection status. Data
will be collected at the time of surgery on surgery-related variables and surgical and
post-operative complications. Additional data will be collected on any surgical
complications and early recurrence at the two-week visit when sutures will be removed. A
follow up visit at two months will include data collection on recurrence and presence of
ocular infection. Evaluations for trichiasis recurrence will occur again at six months and
at one year post-surgery. The latter visit will also include data collection on presence of
ocular infection in the surgical case, and ocular infection in household members. Evaluation
of the risk of recurrence at six months and one year within each group will be completed to
determine the benefit of using azithromycin compared to topical tetracycline, and the added
benefit of family-based treatment.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Presence of trichiasis:
- no previous report of trichiasis surgery in at least one eye with trichiasis:
- Agreement by at least one other family member accompanying the patient that, if the
patient is randomized to the family-treatment arm, s/he also would be willing to
receive antibiotic treatment
- Age 18 or older
Exclusion Criteria:
- other household members concurrently participating in the trial
- Self-reported pregnancy
- Documented allergy to tetracycline
- Plans to move out of the region within 1 year.
Locations and Contacts
Johns Hopkins University, Baltimore, Maryland 21205, United States
Additional Information
Related publications: Melese M, West ES, Alemayehu W, Munoz B, Worku A, Gaydos CA, West SK. Characteristics of trichiasis patients presenting for surgery in rural Ethiopia. Br J Ophthalmol. 2005 Sep;89(9):1084-8. West ES, Munoz B, Imeru A, Alemayehu W, Melese M, West SK. The association between epilation and corneal opacity among eyes with trachomatous trichiasis. Br J Ophthalmol. 2006 Feb;90(2):171-4. West ES, Alemayehu W, Munoz B, Melese M, Imeru A, West SK. Surgery for Trichiasis, Antibiotics to prevent Recurrence (STAR) Clinical Trial methodology. Ophthalmic Epidemiol. 2005 Aug;12(4):279-86.
Starting date: August 2001
Ending date: December 2006
Last updated: July 3, 2006
|